已核实 DOI PubMed 相关产品: 2

Nano-gold micelles loaded Dox and Elacridar for reversing drug resistance of breast cancer

Journal 2022 · IF 2.05 · 17(2): 49-60 · 发表于 2022 年 11 月 7 日
作者: Liu-Jing Wen,Yue-Sheng Wang,Jie Zhang
阅读全文 在 PubMed 查看

摘要

The aim of this study was to provide a new effective carrier for rescuing the sensitivity of drug-resistant in breast cancer cells. Nano-gold micelles loaded with Dox and Elacridar (FP-ssD@A-E) were chemically synthesised. With the increase in the amount of Dox and Elacridar, the encapsulation rate of FP-ssD@A-E gradually increased, and the drug loading rate gradually decreased. FP-ss@A-E had a sustained-release effect. Dox, Elacridar, FP-ss@AuNPs, and FP-ssD@A-E significantly improved cell apoptosis, in which, FP-ssD@A-E was the most significant. FP-ssD@A-E significantly decreased the cell viability and improved the Dox uptake. The levels of VEGFR-1, P-gp, IL-6, and i-NOS were significantly decreased after Dox, Dox + Elacridar, FP-ss@AuNPs, and FP-ssD@A-E treatment. It was worth noting that FP-ssD@A-E had the most significant effects. The prepared FP-ssD@A-E micelles, which were spherical in shape, uniform in particle size distribution, and had good drug loading performance and encapsulation efficiency.

本研究中使用的阿拉丁产品

2 款产品在本文中被引用